Botulinum Toxin for Pediatric Migraine: A Retrospective Multisite Cohort Study

Background: Onabotulinum toxin A is effective in adult chronic migraine, but the efficacy is not well established in adolescent patients. The objective of this study is to describe the safety and efficacy of onabotulinum toxin A and incobotulinum toxin A for adolescent chronic migraine headache. Methods: We performed a chart review of adolescents who received onabotulinum toxin A or incobo-tulinum toxin A for headache prevention. Demographic information and baseline headache character-istics were collected. The primary end point was a 50% reduction in headache frequency. Secondary outcome measures included reduction in headache frequency, repeat appointments for injections, reduction in other migraine medications, and adverse events. Results: We included 51 adolescents who received at least one injection of either incobotulinum toxin A or onabotulinum toxin A for chronic migraine. Mean age at first dose was 16.0 (1.1; 13 to 17), (S.D. and range). Patients averaged 24.0 headache days per month (7.6; 4 to 28), (S.D. and range) before injection. In addition, 36 of the 51 adolescents (71%) were experiencing continuous headaches. Thirty-five (69%) adolescents had experienced 50% reduction in headache days by the time of first follow-up, which occurred on average at 16.6 weeks from initial injection (11.5; 2 to 55.7) (S.D. and range). Adolescents reported an average decrease of 13.1 headaches days per month. Only two adolescents reported side effects (4%), which were neck soreness and headache following injection. Conclusions: Botulinum toxin had better efficacy in our adolescent migraine population than has been demonstrated in other studies. & COPY; 2023 Elsevier Inc. All rights reserved.

Automated summary

This study aimed to describe the safety and efficacy of onabotulinum toxin A and incobotulinum toxin A for adolescent chronic migraine headache. The results showed that adolescents experienced an average decrease of 13.1 headache days per month and 69% of them had a 50% reduction in headache days by the time of first follow-up. Overall, these treatment methods demonstrated better efficacy in adolescent chronic migraine patients, with only a few patients experiencing some side effects.